Biohit Oyj Press Release May 6, 2014 at 9 a.m. local time (EEST)
Acetium capsules, developed and patented by Biohit Oyj, seems to improve gastric acid secretion in patients with acid-free stomach (atrophic gastritis) caused by either H. pylori or autoimmune disorder. The results were presented in the major international meeting for gastroenterologists (Digestive Disease Week) in Chicago, May 4, 2014.
An Italian study showed for the first time in the world that 6 months Acetium® treatment ( 3 capsules per day) significantly improve the function of acid free stomach. So far, in particular auto-immune disorder related acid-free stomach has been considered to be irreversible disease condition. The study included 30 patients who had either moderate or severe atrophic gastritis. On the basis of blood tests, L-cysteine treatment significantly increased the ability of gastric mucosa to secrete pepsinogen, which reflects the gastric acid-secreting cell mass. In addition, treatment significantly reduced blood levels of gastrin-17, which in turn indicates increased gastric acid secretion.
Recovery of Gastric Function after Acetium Administration: a 6 Months Study in Atrophic Gastritis Subjects.
Francesco Di Mario1, Hunor Pal Farkas3, Francesco Ferrara1, Nadia Dal Bo1, Tiziana Slongo1, Roberto Marcello1, Massimo Rugge2, Carmelo Scarpignato4
1Department of Specialist Medicine, Gastroenterology Unit, Treviso General Hospital, Treviso, Italy; 2Department of Diagnostic Medical Sciences and Special Therapies, Surgical Pathology and Cytopathology Unit, University of Padova, Padova, Italy; 3Department of Internal Medicine, Gastroenterology Unit, Mure, County Emergency Hospiral, Tagu Mures, Romania; 4Department of Clinical Sciences, Laboratory of Clinical Phramacology, University of Parma, Parma, Italy
Professor Di Mario: ‘So far atrophic gastritis has been considered to be an irreversible disease condition. For the first time it seems possible to cure atrophic gastritis.”
CEO Semi Korpela, Biohit Oyj: “The results look promising and warrant for further placebo controlled trials with larger materials.’
Attachment: Additional information on Acetium capsule
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
